Most Recent Articles by Diana Ernst, RPh
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.
Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
"This is the first report of decreased insulin requirements in a patient with [T1D] correlating with micafungin administration," noted the authors.
The impurity was identified following laboratory testing conducted by the Food and Drug Administration (FDA); this is the first non-valsartan product that the Agency has found to contain NDEA.
For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.
More Articles by Diana Ernst, RPh
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Sleep Quality in Women With Surgical vs Natural Menopause
- Unhealthy Lifestyle and Rotating Night Shifts Put Nurses at Higher Risk for T2D
- Serious Adverse Events Linked to SGLT2 Inhibitors
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- History of Partner Violence Tied to Menopause Symptoms
- Patients Commonly Withhold Medically Relevant Information From Clinicians
- "Gender Panic" in Clinical Settings: Protecting Public Accommodations Access for Transgender Individuals